UFT/oral calcium folinate plus radiation in pancreatic cancer

A phase I, single-center, open-label, dose-escalation study (University of Alabama [UAB] 9614) has been undertaken to evaluate the feasibility and saf ety of uracil and tegafur (in a molar ratio of 4:1 [UFT]) plus oral calcium folinate (Orzel) plus radiotherapy in patients with pancreatic cancer. A f etal of 11 patients with a median age of 59 years have been treated for 35 days with 150 mg/m(2)/day of UFT and 90 mg/day of oral calcium folinate, di vided into three daily doses. Radiotherapy began on day 1, to a total dose of 45 Gy at 1.8 Gy per day (for approximately 5 weeks). Dose escalation of UFT will be performed until the maximum tolerated dose is defined, Overall, therapy has been well tolerated and the maximum tolerated dose has not yet been reached.